Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...
Optimism Over Global Healthcare Sector Rises: Jefferies
Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA Vaccine Official Says RFK Jr. Nomination Is a Chance for Scientist to Make the Case for Vaccines"
Live On CNBC, Josh Brown Announces Cut Pfizer Position By Half
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Citi Research's U.S. Equity Strategy Large-Cap Recommendation List